Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 9:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 13,649 matching trials from the live ClinicalTrials.gov search.
Conditions
Breast Cancer
Interventions
brachytherapy
Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
216
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 167 more
Conditions
Metastatic Ureter Carcinoma, Metastatic Urethral Carcinoma, Stage III Bladder Urothelial Carcinoma AJCC v6 and v7, Stage III Ureter Cancer AJCC v7, Stage III Urethral Cancer AJCC v7, Stage IV Bladder Urothelial Carcinoma AJCC v7, Stage IV Ureter Cancer AJCC v7, Stage IV Urethral Cancer AJCC v7, Ureter Urothelial Carcinoma, Urethral Urothelial Carcinoma
Interventions
Eribulin Mesylate, Gemcitabine Hydrochloride
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
17
States / cities
Duarte, California • Los Angeles, California • Pasadena, California + 12 more
Active, not recruiting Phase 2 Interventional Results available

Dexamethasone in Controlling Dyspnea in Patients With Cancer

NCT03367156
Conditions
Dyspnea, Malignant Neoplasm
Interventions
Dexamethasone, Placebo, Questionnaire Administration
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
3
States / cities
Houston, Texas
Conditions
Melanoma (Skin)
Interventions
ALVAC-hB7.1, canarypox-hIL-12 melanoma vaccine
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Birmingham, Alabama
Conditions
Subclinical Hypercortisolism, Cushing Syndrome, Adrenal Neoplasm
Interventions
Adrenalectomy, Observation
Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Acute Leukemias of Ambiguous Lineage, B-cell Adult Acute Lymphoblastic Leukemia, Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Burkitt Lymphoma
Interventions
cyclophosphamide, vincristine sulfate, prednisone, inotuzumab ozogamicin, laboratory biomarker analysis
Drug · Biological · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
5
States / cities
Duarte, California • Palo Alto, California • Rochester, New York + 2 more
Not listed No phase listed Observational Accepts healthy volunteers

Social Contextual Influences on Physical Activity

NCT01195337
Conditions
Cancer, Prevention Harmful Effects
Interventions
PA Prescription Plan, Pedometer, Newsletters
Behavioral · Device
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
25 Years to 60 Years
Enrollment
336 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2020
U.S. locations
1
States / cities
Houston, Texas
Conditions
Extensive Stage Lung Small Cell Carcinoma, Recurrent Lung Small Cell Carcinoma
Interventions
Carboplatin, Cisplatin, Etoposide, Laboratory Biomarker Analysis, Placebo Administration, Sunitinib Malate
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
125
States / cities
Arroyo Grande, California • Castro Valley, California • Emeryville, California + 81 more
Conditions
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions
Dexamethasone, Ixazomib, Lenalidomide
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
4
States / cities
Atlanta, Georgia • Ann Arbor, Michigan • St Louis, Missouri
Conditions
Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
Interventions
belinostat
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
Acute Myeloid Leukemia in Remission, FLT3 Gene Mutation, Hematologic and Lymphocytic Disorder, Acute Myeloid Leukemia, Minimal Residual Disease Persistence, Therapy-Related Acute Myeloid Leukemia
Interventions
Azacitidine, Venetoclax
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
1
States / cities
Houston, Texas
Conditions
Anal Canal Squamous Cell Carcinoma, Metastatic Anal Canal Carcinoma, Stage IV Anal Cancer AJCC v8
Interventions
Biospecimen Collection, Computed Tomography, Ipilimumab, Magnetic Resonance Imaging, Nivolumab
Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
55
States / cities
Los Angeles, California • Sacramento, California • Aurora, Colorado + 43 more
Conditions
Brain Tumors, Central Nervous System Tumors, Neuroblastoma, Sarcoma
Interventions
filgrastim, carboplatin, cisplatin, cyclophosphamide, etoposide, thiotepa, vincristine sulfate, conventional surgery, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 2 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2011
U.S. locations
66
States / cities
Duarte, California • Los Angeles, California • Madera, California + 52 more
Conditions
Leukemia
Interventions
Filgrastim, Busulfan, Cyclophosphamide, Cyclosporine, Decitabine (DAC), Methotrexate, Methylprednisolone, Tacrolimus, Allogeneic Bone Marrow Transplantation, Peripheral Blood Stem Cell Transplantation
Biological · Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
15 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2002
U.S. locations
1
States / cities
Houston, Texas
Conditions
Colorectal Cancer, Endometrial Cancer, Head and Neck Cancer, Liver Cancer, Lung Cancer, Melanoma (Skin), Pancreatic Cancer, Testicular Germ Cell Tumor, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
aldesleukin, ras peptide cancer vaccine, sargramostim, DetoxPC
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Neurofibromatosis 1
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Recurrent Glioblastoma, Recurrent Gliosarcoma
Interventions
EGFRvIII-CARs
Biological
Lead sponsor
Gary Archer Ph.D.
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Recruiting No phase listed Observational Accepts healthy volunteers

Specimen and Data Study for Ovarian Cancer Early Detection and Prevention

NCT00005095
Conditions
Cervical Cancer, Endometrial Cancer, Fallopian Tube Cancer, Hereditary Breast/Ovarian Cancer (brca1, brca2), Ovarian Cancer, Sarcoma, Uterine Leiomyomata, Vaginal Cancer, Vulvar Cancer
Interventions
Ca-125, screening questionnaire administration, Surgery
Other · Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
6,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2040
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Gastrointestinal Stromal Tumor, Sarcoma
Interventions
semaxanib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
2
States / cities
Boston, Massachusetts
Conditions
Pancreatic Acinar Cell Carcinoma
Interventions
Olaparib, ECG, CT CAP, Tumor Biopsy
Drug · Diagnostic Test · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Recurrent Cutaneous Squamous Cell Carcinoma of the Head and Neck, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck, Stage II Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8
Interventions
Cemiplimab
Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Houston, Texas
Conditions
Adult Grade III Lymphomatoid Granulomatosis, AIDS-related Peripheral/Systemic Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Stage III Adult Burkitt Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Mixed Cell Lymphoma, Stage III Adult Diffuse Small Cleaved Cell Lymphoma, Stage III Adult Hodgkin Lymphoma, Stage III Adult Immunoblastic Large Cell Lymphoma, Stage III Adult Lymphoblastic Lymphoma, Stage III Adult T-cell Leukemia/Lymphoma, Stage III Cutaneous T-cell Non-Hodgkin Lymphoma, Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Grade 3 Follicular Lymphoma, Stage III Mantle Cell Lymphoma, Stage III Marginal Zone Lymphoma, Stage III Mycosis Fungoides/Sezary Syndrome, Stage III Small Lymphocytic Lymphoma, Stage IV Adult Burkitt Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Mixed Cell Lymphoma, Stage IV Adult Diffuse Small Cleaved Cell Lymphoma, Stage IV Adult Hodgkin Lymphoma, Stage IV Adult Immunoblastic Large Cell Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Stage IV Adult T-cell Leukemia/Lymphoma, Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IV Marginal Zone Lymphoma, Stage IV Mycosis Fungoides/Sezary Syndrome, Stage IV Small Lymphocytic Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific, Waldenström Macroglobulinemia
Interventions
tanespimycin, bortezomib, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Smoking Cessation
Interventions
Counselor-Initiated Tobacco Quit Line, Self-Paced Tobacco Quit Line
Other
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
18 Years and older
Enrollment
946 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Memphis, Tennessee
Conditions
Breast Cancer
Interventions
LUM Imaging System
Combination Product
Lead sponsor
Lumicell, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
16
States / cities
Mobile, Alabama • Palo Alto, California • New Haven, Connecticut + 13 more